[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585828":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"University of California, Davis","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Single arm study comparing two different needle biopsy systems for prostate biopsy",null,[12],"Diagnostic Test: Comparison of Biopsy Needle Types for Prostate Biopsy",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","Comparison of Biopsy Needle Types for Prostate Biopsy","Each patient will undergo a standard of care prostate biopsy according to the clinical indication alternating between the SureCore and standard Bard needle",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Marc Dall'Era, MD","CONTACT","916-734-2893","mdallera@ucdavis.edu",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Elisa Lee","916-734-5173","elilee@ucdavis.edu",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"UC Davis Departments of Urologic Oncology","RECRUITING","Sacramento","California","95817","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-121.4944,38.58157,{"lat":42,"lon":41},[45],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100585828","comparison-of-new-surecore-biopsy-of-needle-to-standard-of-care-during-transperineal-prostate-biopsies-100585828",false,"NCT06907446","Comparison of New SUREcore Biopsy of Needle to Standard of Care During Transperineal Prostate Biopsies","Comparison of BARD Max Core 18g Needle With Uro1 SUREcore 18g Needle in Targeted Prostate Biopsies","Inclusion Criteria:\n\n* Patient older than age of 18 undergoing prostate biopsy\n\nExclusion Criteria:\n\n* Unable to consent\n* Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives\n* Prisoners","MALE","18 Years",{"count":58,"type":59},50,"ESTIMATED","INTERVENTIONAL",[62],"NA","To study a novel biopsy needle system for performing transperineal prostate biopsy. Prostate biopsy remains the standard approach for prostate cancer detection. While pre-biopsy MRI allows for targeting of visible lesions, systemic or 'off target' samples are recommended due to the well-recognized risk of undegrading and under sampling with current commercially available needles. The SureCore plus single-use biopsy needle produces a more intact tissue core with a same caliber 18g needle with \\~21% more tissue per core in pre-clinical studies. This research study will determine if a new biopsy needle designed to produce more robust tissue cores per sample can improve detection and characterization of prostate cancer.",[65],"Prostate Cancer","2026-08-04",{"date":68,"type":69},"2026-08-06","ACTUAL",{"date":71,"type":69},"2025-05-01",{"date":73,"type":59},"2027-12-01",{"name":5,"class":6},1]